Prognosis depends on the stage of disease at presentation, the histology of the tumor, and the location of the primary tumor.[70]Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):717-28.
http://www.ncbi.nlm.nih.gov/pubmed/16253896?tool=bestpractice.com
In patients with bronchial carcinoid tumors who have curative surgical resections, the 10-year survival of typical carcinoids is 85%, and of an atypical carcinoid is 35% at 10 years.[71]Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998 Aug;22(8):934-44.
http://www.ncbi.nlm.nih.gov/pubmed/9706973?tool=bestpractice.com
The risk of recurrence also depends on histology, with 2% recurrence in typical carcinoids and 20% recurrence in atypical carcinoid.[72]Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000 Aug;18(2):156-61.
http://www.ncbi.nlm.nih.gov/pubmed/10925223?tool=bestpractice.com
Midgut tumors often present with advanced disease, hence the development of carcinoid syndrome. For patients with a mesenteric mass without evidence of hepatic metastases, the 5-year survival from one study was reported to be 91% following surgery for the mesenteric metastases.[73]Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002 Aug;26(8):991-7.
http://www.ncbi.nlm.nih.gov/pubmed/12016480?tool=bestpractice.com
Patients with distal metastatic disease used to have a 5-year survival of around 50%; however, this has improved to >65%.[74]Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89(4):471-6.
http://www.ncbi.nlm.nih.gov/pubmed/19174605?tool=bestpractice.com
[75]Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009 Sep;16(3):885-94.
http://erc.endocrinology-journals.org/content/16/3/885.long
http://www.ncbi.nlm.nih.gov/pubmed/19458024?tool=bestpractice.com
Younger patients (≤50 years) have a more favorable prognosis. Unfavorable factors for survival include carcinoid heart disease, high-grade tumors, and extra-abdominal metastases.